Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 20, 2007

Cannasat Taps IntelGenx to Facilitate Development of Cannabinoid-Based Products for Mood Disorders

  • Cannasat Therapeutics and IntelGenx will together develop a cannabinoid-based product through a combination of Cannasat's and IntelGenx's drug delivery technologies. CAT 320 targets the endocannabinoid system to treat mood disorders, such as anxiety and depression.

    Cannasat will leverage IntelGenx' experience in developing oral, sublingual, and transdermal formulations. IntelGenx' will help address the challenges of achieving rapid onset, improving therapeutic efficacy, and minimizing the total dose required to treat disease conditions.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.